SHANGHAI, China, Aug. 12, 2021 /PRNewswire/ -- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare
services company offering patient management, online healthcare
information, professional training and educational services, today
announced that its subsidiary Shanghai Zhongxin Medical Technology
Co., Ltd. ("Zhongxin") launches Treatment Outcome Oriented DOT
Management System ("DOT Management System") to accelerate the
development of patient management business, meeting the increasing
demand in tumor and rare disease patient management market.
In the early stage of treatment for tumor and rare disease, many
patients discontinue medications due to lack of confidence in the
efficacy of the medications or adverse reactions to the medication.
The DOT Management System launched by Zhongxin is designed to
address this situation. DOT stands for duration of therapy.
Antineoplastic drugs need certain treatment time to take effect,
and as a result, the length of DOT affects the progression and
risks of disease. The DOT Management System aims at improving
patient treatment outcomes, by evaluating curative effects through
medical models and predicting and warning patients of possible
adverse reactions. Meanwhile, the DOT Management System will
establish a refined plan based on each patient's condition and
carry out effective interventions such as providing corresponding
education and guidance for each patient to let them learn in
advance any possible adverse reactions or any feasible measures to
relieve such adverse reactions during their medications, in order
to ease patients' concerns or fears of adverse reactions, guarantee
their duration of therapy and improve their adherence to treatment
for the goal of treatment outcome improvements.
DOT is the key to deliver maximum benefits to patients as it
allows for the maximum efficacy of drugs. DOT also directly affects
the clinical application and market sales of drugs, becoming a new
engine for the development of the oncology drug market. In recent
years, more and more pharmaceutical companies realize that DOT
management is a key factor affecting the ultimate market
performance of their drugs. Zhongchao is able to seize the
ever-growing market opportunities for organic growth with its
extensive pharmaceutical company client resources, in-depth service
experience, and advantages in innovative service product
development. The launch of DOT Management System may not only help
improve patient treatment but also deepen the cooperation between
the Company and pharmaceutical companies, achieving a multi-win
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is an online
provider of healthcare information, professional training and
educational services to healthcare professionals under its "MDMOOC"
platform (www.mdmooc.org) and to the public under its "Sunshine
Health Forums" platform (www.ygjkclass.com) in China. The Company also provides patient
management services through its subsidiaries. More information
about the Company can be found at its investor relations website at
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the
Company's future business development; product and service demand
and acceptance; changes in technology; economic conditions; the
growth of the professional training and educational services market
in China and the other
international markets the Company plans to serve; reputation and
brand; the impact of competition and pricing; government
regulations; fluctuations in general economic and business
conditions in China and the
international markets the Company plans to serve and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC, the length
and severity of the recent coronavirus outbreak, including its
impacts across our business and operations. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
SEC, which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward–looking
statements to reflect events or circumstances that arise after the
For more information, please contact:
At the Company: Pei Xu, CFO
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Phone: +1 718-213-7386
SOURCE Zhongchao Inc.